Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.8%

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) fell 5.8% on Tuesday . The company traded as low as $27.11 and last traded at $27.20. 120,658 shares traded hands during trading, a decline of 36% from the average session volume of 189,764 shares. The stock had previously closed at $28.87.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DNTH. Lifesci Capital raised shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Jefferies Financial Group raised their price objective on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, March 22nd. HC Wainwright assumed coverage on shares of Dianthus Therapeutics in a report on Thursday, May 16th. They set a “buy” rating and a $40.00 price objective on the stock. Cantor Fitzgerald assumed coverage on shares of Dianthus Therapeutics in a report on Thursday, June 27th. They issued an “overweight” rating on the stock. Finally, Wedbush lifted their target price on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the company an “outperform” rating in a report on Friday, May 10th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $42.83.

Dianthus Therapeutics Trading Down 6.3 %

The business’s fifty day moving average price is $23.88 and its 200 day moving average price is $21.80. The firm has a market capitalization of $793.92 million, a price-to-earnings ratio of -4.65 and a beta of 1.88.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The company had revenue of $0.87 million for the quarter, compared to analysts’ expectations of $0.48 million. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC purchased a new stake in shares of Dianthus Therapeutics during the 4th quarter worth $25,000. Citigroup Inc. purchased a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth $53,000. Virtu Financial LLC purchased a new stake in shares of Dianthus Therapeutics during the 1st quarter worth $390,000. Laurion Capital Management LP purchased a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth $497,000. Finally, Hussman Strategic Advisors Inc. purchased a new stake in shares of Dianthus Therapeutics during the 1st quarter worth $630,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.